logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

ANTENGENE-B (06996) spent approximately HK$504,100 on 173,000 shares on October 26.

date
20:28 26/10/2026
avatar
GMT Eight
ANTENGENE-B (06996) announced that on October 26, 2026, it spent approximately HK$504,100 on 173,000 shares.
ANTENGENE-B (06996) announced that on October 26, 2026, it spent approximately HK$504,100 on 173,000 shares.
Related Articles
US Stock Market Move | Brazil Election Results Spook Markets; Brazil-Linked Assets Listed in the US Plunge
US Stock
SpaceX (SPACX.US) is not holding back on expanding AI computing power! It has reached a US$40 billion GPU equipment financing lease agreement with Apollo Global Management Inc (APO.US).
Phase 3 data meets targets but stock still sold off! Citi maintains "Sell" rating on Moderna (MRNA.US), $80 price target implies over 60% downside
US Stock Market Move | Brazil Election Results Spook Markets; Brazil-Linked Assets Listed in the US Plunge
SpaceX (SPACX.US) is not holding back on expanding AI computing power! It has reached a US$40 billion GPU equipment financing lease agreement with Apollo Global Management Inc (APO.US).
US Stock
Phase 3 data meets targets but stock still sold off! Citi maintains "Sell" rating on Moderna (MRNA.US), $80 price target implies over 60% downside
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.